Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis

Molecular Cancer

Volumn 8, Issue , 2009, Pages

  Pollizzi, Kristen ^a   Malinowska Kolodziej, Izabela ^a   Stumm, Michael ^b   Lane, Heidi ^b   Kwiatkowski, David ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; ANTINEOPLASTIC AGENT; EVEROLIMUS; KI 67 ANTIGEN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; UNCLASSIFIED DRUG; CARRIER PROTEIN; DRUG DERIVATIVE; ETHYLNITROSOUREA; FRAP1 PROTEIN, MOUSE; IMIDAZOLE DERIVATIVE; MTORC1 PROTEIN, MOUSE; NVP BEZ235; PHOSPHOTRANSFERASE; QUINOLINE DERIVATIVE; RAPAMYCIN; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME INHIBITION; GENE EXPRESSION; KIDNEY TUMOR; LOW DRUG DOSE; MOUSE; NONHUMAN; TREATMENT DURATION; TREATMENT RESPONSE; TUBEROUS SCLEROSIS; TUMOR GROWTH; TUMOR VOLUME; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TUMOR RECURRENCE;

MUS;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTINEOPLASTIC AGENTS; CARRIER PROTEINS; DISEASE MODELS, ANIMAL; ETHYLNITROSOUREA; IMIDAZOLES; KIDNEY NEOPLASMS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASM RECURRENCE, LOCAL; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); QUINOLINES; SIGNAL TRANSDUCTION; SIROLIMUS; TRANSCRIPTION FACTORS; TUBEROUS SCLEROSIS;

EID: 67650077581     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-8-38     Document Type: Article

References (20)

1. Crino PB Nathanson KL Henske EP The tuberous sclerosis complex N Engl J Med 2006, 355:1345-56. 10.1056/NEJMra055323 17005952
2. Bissler JJ Kingswood JC Renal angiomyolipomata Kidney Int 2004, 66:924-34. 10.1111/j.1523-1755.2004.00838.x 15327383
3. McCormack FX Lymphangioleiomyomatosis: A clinical update Chest 2008, 133:507-16. 10.1378/chest.07-0898 18252917
4. Onda H Lueck A Marks PW Warren HB Kwiatkowski DJ Tsc2(+/-) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background J Clin Invest 1999, 104:687-95. 408440 10491404 10.1172/JCI7319
5. Kwiatkowski DJ Zhang H Bandura JL Heiberger KM Glogauer M el-Hashemite N Onda H A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells Hum Mol Genet 2002, 11:525-34. 10.1093/hmg/11.5.525 11875047
6. Inoki K Corradetti MN Guan KL Dysregulation of the TSC-mTOR pathway in human disease Nat Genet 2005, 37:19-24. 10.1038/ng1494 15624019
7. Guertin DA Sabatini DM Defining the role of mTOR in cancer Cancer Cell 2007, 12:9-22. 10.1016/j.ccr.2007.05.008 17613433
8. Kenerson H Dundon TA Yeung RS Effects of rapamycin in the Eker rat model of tuberous sclerosis complex Pediatr Res 2005, 57:67-75. 10.1203/ 01.PDR.0000147727.78571.07 15557109
9. Lee L Sudentas P Donohue B Asrican K Worku A Walker V Sun Y Schmidt K Albert MS El-Hashemite N Lader AS Onda H Zhang H Kwiatkowski DJ Dabora SL Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models Genes Chromosomes Cancer 2005, 42:213-27. 10.1002/ gcc.20118 15578690
10. Harrington LS Findlay GM Gray A Tolkacheva T Wigfield S Rebholz H Barnett J Leslie NR Cheng S Shepherd PR Gout I Downes CP Lamb RF The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins J Cell Biol 2004, 166:213-23. 2172316 15249583 10.1083/ jcb.200403069
11. Zhang H Cicchetti G Onda H Koon HB Asrican K Bajraszewski N Vazquez F Carpenter CL Kwiatkowski DJ Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR J Clin Invest 2003, 112:1223-33. 213485 14561707
12. O'Reilly KE Rojo F She QB Solit D Mills GB Smith D Lane H Hofmann F Hicklin DJ Ludwig DL Baselga J Rosen N mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt Cancer Res 2006, 66:1500-8. 10.1158/0008-5472.CAN-05-2925 16452206
13. Maira S Stauffer F Brueggen J Furet P Schnell C Fritsch C Brachmann S Chène P De Pover A Schoemaker K Fabbro D Gabriel D Simonen M Murphy L Finan P Sellers W García-Echeverría C Identification and characterization of NVP-BEZ235, a new orally available dual PI3K/mTOR inhibitor with potent in vivo antitumor activity Mol Cancer Ther 2008, 7:1851-63. 10.1158/1535-7163.MCT-08-0017 18606717
14. El-Hashemite N Walker V Kwiatkowski DJ Estrogen enhances whereas tamoxifen retards development of Tsc mouse liver hemangioma: A tumor related to renal angiomyolipoma and pulmonary lymphangioleiomyomatosis Cancer Res 2005, 65:2474-81. 10.1158/0008-5472.CAN-04-3840 15781664
15. Breuleux M Klopfenstein M Stephan C Doughty CA Barys L Maira SM Kwiatkowski D Lane HA Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition Mol Cancer Ther 2009, 8:742-53. 10.1158/ 1535-7163.MCT-08-0668 19372546
16. Bissler JJ McCormack FX Young LR Elwing JM Chuck G Leonard JM Schmithorst VJ Laor T Brody AS Bean J Salisbury S Franz DN Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis N Engl J Med 2008, 358:140-51. 10.1056/NEJMoa063564 18184959
17. Davies DM Johnson SR Tattersfield AE Kingswood JC Cox JA McCartney DL Doyle T Elmslie F Saggar A de Vries PJ Sampson JR Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis N Engl J Med 2008, 358:200-3. 10.1056/NEJMc072500 18184971
18. Manning BD Logsdon MN Lipovsky AI Abbott D Kwiatkowski DJ Cantley LC Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2 Genes Dev 2005, 19:1773-8. 1182339 16027169 10.1101/gad.1314605
19. Sarbassov DD Guertin DA Ali SM Sabatini DM Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex Science 2005, 307:1098-101. 10.1126/science.1106148 15718470
20. Sarbassov DD Ali SM Sengupta S Sheen JH Hsu PP Bagley AF Markhard AL Sabatini DM Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB Mol Cell 2006, 22:159-68. 10.1016/j.molcel.2006.03.029 16603397